Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Scopus Biopharma Inc (SCPS)

Scopus Biopharma Inc (SCPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4
  • Shares Outstanding, K 42,084
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,610 K
  • 60-Month Beta -0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SCPS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 +200.00%
on 09/12/24
0.0003 unch
on 09/18/24
+0.0002 (+200.00%)
since 08/16/24
3-Month
0.0001 +200.00%
on 09/12/24
0.0003 unch
on 09/18/24
+0.0001 (+50.00%)
since 06/14/24
52-Week
0.0001 +200.00%
on 09/12/24
0.0673 -99.55%
on 09/26/23
-0.0397 (-99.25%)
since 09/15/23

Most Recent Stories

More News
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present onTLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company

Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card

Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma to Present at the LD Micro Main Event

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in...

SCPS : 0.0003 (+200.00%)
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

SCPS : 0.0003 (+200.00%)
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases...

SCPS : 0.0003 (+200.00%)

Business Summary

Scopus BioPharma Inc. is a biopharmaceutical company. Its lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs,...

See More

Key Turning Points

3rd Resistance Point 0.0003
2nd Resistance Point 0.0003
1st Resistance Point 0.0003
Last Price 0.0003
1st Support Level 0.0003
2nd Support Level 0.0003
3rd Support Level 0.0003

See More

52-Week High 0.0673
Fibonacci 61.8% 0.0416
Fibonacci 50% 0.0337
Fibonacci 38.2% 0.0258
Last Price 0.0003
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar